The National Medical Insurance Administration publicly solicits opinions on negotiating drug contract renewals and bidding for non-exclusive drugs

According to Xinhua News Agency, Beijing, July 4th, in conjunction with the 2023 national basic medical insurance, work-related injury insurance and maternity insurance drug catalog management priorities, the National Medical Insurance Administration issued the “Negotiating Drug Contract Renewal Rules (2023 Edition Consultation Draft)” on the 4th. Bidding Rules for Non-exclusive Drugs (Draft for Comments)”, open to the public for comments.

Compared with the 2022 Negotiation Drug Contract Renewal Rules, the “Negotiation Drug Contract Renewal Rules (2023 Edition Consultation Draft)” has increased the conditions for being clearly included in the regular catalog management. Drugs negotiated within the period” for more than 8 years (calculated from 2018 for the negotiated drugs in the 2017 version of the list, calculated from 2019 for the negotiated drugs in the 2018 version of the list, and calculated based on the implementation year of the list in 2019 and later).

The “Non-exclusive Drug Bidding Rules (Draft for Comment)” proposes that if a drug is included in the medical insurance catalog through bidding, the lowest price quoted by each company will be taken as the payment standard for the generic drug. If the company’s quotation is lower than 70% of the medical insurance willingness to pay, 70% of the medical insurance willingness to pay will be used as the payment standard for the drug.

The public can submit comments and suggestions before 17:00 on July 10, 2023, and send feedback to the National Medical Insurance Administration in writing or email. (Peng Yunjia and Mu Tiecheng)

Disclaimer: The content of this article comes fromBeijing NewsThe opinions expressed in the article do not represent the position of this site. If your rights are violated or false statements are involved, please contact us.